ABVX
What one share of Abivax S.A. holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies.
Abivax S.A.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$5.47 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.62 |
| Cash and investments | $7.72 |
| Book value | $6.80 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$3.25 | $0.00 | −$3.45 | — | $1.75 |
| 2022 | — | −$3.35 | $0.02 | −$2.99 | — | $0.34 |
| 2023 | — | −$3.71 | $0.01 | −$2.45 | — | $3.45 |
| 2024 | — | −$3.02 | $0.01 | −$2.66 | — | $0.66 |
| 2025 | — | −$5.47 | $0.00 | −$2.62 | — | $6.80 |